Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole-Reference-Cited by-同舟云学术

Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

Published:2020-10-16 Issue:1 Volume:46 Page:41-51
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Le Merdy Maxime,Tan Ming-Liang,Sun Dajun,Ni Zhanglin,Lee Sue-Chih,Babiskin Andrew^ORCID,Zhao Liang

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13318-020-00649-x.pdf

Reference35 articles.

1. Grimm SW, Einolf HJ, Hall SD, He K, Lim H-K, Ling K-HJ, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos Biol Fate Chem. 2009;37:1355–70.

2. Gajendran J, Krämer J, Shah VP, Langguth P, Polli J, Mehta M, et al. Biowaiver monographs for immediate-release solid oral dosage forms: nifedipine. J Pharm Sci. 2015;104:3289–98.

3. US. FDA. PROCARDIA® (nifedipine) CAPSULES For Oral Use [Internet]. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018482s051lbl.pdf. Accessed 20 Aug 2020.

4. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1986;261:5051–60.

5. Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos Biol Fate Chem. 2011;39:2020–33.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Solubility Enhancement of Omeprazole: A Comprehensive Review;Research Journal of Pharmaceutical Dosage Forms and Technology;2024-05-28

2. Use of physiologically‐based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine;CPT: Pharmacometrics & Systems Pharmacology;2023-12-21

3. Physiologically based pharmacokinetic modeling to assess the drug-drug interactions of anaprazole with clarithromycin and amoxicillin in patients undergoing eradication therapy of H. pylori infection;European Journal of Pharmaceutical Sciences;2023-10

4. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development;Pharmaceutical Research;2022-09-08

5. Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib;Clinical Pharmacology in Drug Development;2022-01-07